Autoimmunity Biologic Solutions Inc.
Last verified 2026-05-07. JSON
| Total raised | $3.2M |
|---|---|
| Latest round | Funding round, $3.2M, 2024-11-08 |
| Founded | unknown |
| Headquarters | HOUSTON, TX |
| Industry | biotechnology |
| Stage | unknown |
| Website | autoimmunitybiologicsolutions.com |
Clinical-stage biotech developing monoclonal antibodies that target soluble IL-7 receptor to dampen autoimmune amplification. Initial programs focus on genetically defined patients with multiple sclerosis and lupus nephritis. Selective sIL7R targeting aims to correct the immune defect rather than broadly suppress immunity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-11-08 | Funding round | $3.2M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $3.2M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $3.2M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | autoimmunitybiologicsolutions.com, read 2026-05-07 |
| Description | self-reported | autoimmunitybiologicsolutions.com, read 2026-05-07 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $3.2M, 2024-11-08 → Funding round, $3.2M, 2024-11-08, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $3.2M, 2024-11-08 → Funding round, $3.2M, 2024-11-08 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes